Welcome to our dedicated page for Lifevantage SEC filings (Ticker: LFVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for LifeVantage Corp’s latest consultant counts or product-line revenue without wading through dense text? Investors typically arrive here asking, “Where can I find LifeVantage’s quarterly earnings report 10-Q filing?” or “How do I track LifeVantage insider trading Form 4 transactions in real time?” This page bundles every SEC disclosure so you no longer jump between scattered EDGAR links.
Stock Titan’s AI reads each LifeVantage 8-K, 10-Q, and 10-K the moment it posts, then delivers plain-English summaries that flag shifts in independent-consultant enrollment, inventory risk and regulatory updates around nutrigenomic claims. Instead of skimming 200-plus pages, you’ll see the numbers that shape margins—net sales by product family, commission expense trends and emerging compliance issues—explained simply.
Use our quick-access tiles to drill into:
- Annual report 10-K simplified – pick out segment revenue, R&D on nutrigenomics and direct-sales compensation disclosures in minutes.
- Quarterly earnings report 10-Q – monitor consultant turnover, inventory levels and cash flow each quarter with AI-annotated highlights.
- Form 4 insider transactions – real-time alerts on LifeVantage executive stock moves so you can spot buying or selling trends fast.
- 8-K material events explained – leadership changes, product-safety notices or distributor policy updates distilled into key takeaways.
- Proxy statement executive compensation – understand how bonuses tie to enrolment growth and nutrigenomic product launches.
Whether you’re comparing quarters, dissecting compensation plans, or simply trying to “understand LifeVantage SEC documents with AI,” this hub keeps every filing current and comprehensible. Save hours, gain clarity, and turn regulatory disclosures into actionable insight.
LifeVantage (LFVN) reported a routine insider equity award. Director Darwin Lewis acquired 13,531 shares of common stock on 11/06/2025 under the company’s outside director compensation program. The price reported was $7.76, defined as the weighted average closing price over the ten trading days ending the day before the grant.
These shares will vest in a single installment on November 6, 2026, contingent on continuous service. Following the grant, Lewis beneficially owns 130,748 shares, held directly.
LifeVantage (LFVN) reported Q1 FY2026 results for the quarter ended September 30, 2025. Revenue was $47.6 million, up slightly from $47.2 million a year ago, as the MindBody GLP-1 System offset lower sales of Protandim and TrueScience. Gross profit was $37.8 million, a 79.5% margin.
Net income rose to $2.2 million from $1.8 million, with diluted EPS of $0.17 versus $0.14. The U.S. delivered $35.2 million in revenue, essentially flat, while Japan increased 3.5% to $6.2 million. Active Independent Consultants grew to 48,000, but total Active Customers declined to 73,000, bringing total Active Accounts to 121,000.
Cash and equivalents were $13.1 million, down from $20.2 million at June 30, 2025, reflecting $2.3 million used in operating activities, $0.6 million in cash dividends ($0.045 per share), and $0.6 million of share repurchases (44,000 shares). The company’s $5.0 million revolving credit facility had no balance outstanding; an amendment now permits use for acquisitions. On October 1, 2025, LifeVantage closed the acquisition of critical assets of LoveBiome, with purchase accounting pending.
Shares outstanding were 12,701,187 as of November 3, 2025.
LifeVantage (LFVN)51,330 shares and adds 16,491 performance RSUs granted on August 26, 2025. The original reported 40,336 shares and omitted this PRSU grant.
It also lists 3,750 PRSUs granted on December 23, 2024. Vesting for the 2024 grant: 50% on August 31, 2025; 30% on August 31, 2026; 20% on August 31, 2027, subject to performance and continued service. The 2025 grant vests 34% on September 10, 2026; 33% on September 10, 2027; and 33% on September 10, 2028. The amendment adds Exhibit 24, Power of Attorney.
Lifevantage (LFVN) disclosed the initial insider holdings of its Chief Information Officer. The officer directly owns 40,336 shares of common stock and holds 3,750 performance restricted stock units (PRSUs) at target eligibility.
The PRSUs were granted on December 23, 2024 and vest only upon achievement of specified financial performance criteria: 50% vested on August 31, 2025, with 30% scheduled for August 31, 2026 and 20% on August 31, 2027. Upon maximum performance achievement, up to 200% of the target number of units may be earned.
Kristen Cunningham, Chief Sales Officer and director at Lifevantage Corp (LFVN), reported an insider sale on 10/01/2025. The filing shows she sold 1,720 shares of Lifevantage common stock at a price of $9.56 per share, leaving her with 136,986 shares owned directly. The Form 4 was signed by a power of attorney on 10/03/2025. This report discloses a routine officer sale and the resulting post-transaction ownership.
Alissa Neufeld, who identifies her role as General Counsel of Lifevantage Corp (LFVN), reported a sale of 1,283 shares of the company's common stock on 10/01/2025 at a reported price of $9.56 per share. After the transaction the filing shows Ms. Neufeld beneficially owns 116,977 shares. The Form 4 is signed and dated 10/03/2025, indicating timely disclosure under Section 16 reporting requirements.
On 10/01/2025 Steven R. Fife, who is listed as President and CEO and a Director of Lifevantage Corp (LFVN), reported a sale of 8,181 shares of the company's common stock at a price of $9.56 per share. After the reported transaction, Mr. Fife's beneficial ownership is listed as 752,820 shares. The Form 4 was signed by a power of attorney on 10/03/2025.
Lifevantage Corp insider Carl Aure, the company's Chief Financial Officer, reported a sale of 1,361 shares of Common Stock on 10/01/2025 at a price of $9.56 per share. The Form 4 shows 159,969 shares remained beneficially owned by Mr. Aure after the transaction. The filing was signed by Alissa Neufeld as Power of Attorney on 10/03/2025.
Julie Boyster, listed as the Chief Marketing Officer of Lifevantage Corp (LFVN), reported a sale of company common stock on 10/01/2025. The Form 4 shows she disposed of 1,835 shares at a price of $9.56 per share. After the transaction she beneficially owned 150,088 shares, held directly. The filing was signed by a power of attorney on 10/03/2025. The form is a standard Section 16 filing reporting insider changes in beneficial ownership and contains no additional remarks or derivative transactions.
FAQ
What is the current stock price of Lifevantage (LFVN)?
What is the market cap of Lifevantage (LFVN)?
